Endovastec(SH:688016) Sou Hu Cai Jing·2025-08-14 13:32Core Viewpoint - The company, Shanghai MicroPort CardioFlow Medtech Co., Ltd., is experiencing a decline in stock price and financial performance, with a current market capitalization of 14.261 billion yuan and a rolling PE ratio of 31.87, which is significantly lower than the industry average of 55.76 [1][2]. Company Overview - The main business of the company includes the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products such as thoracic aortic stent graft systems and abdominal aortic stent graft systems [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For the first quarter of 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% compared to the previous year, with a gross profit margin of 69.61% [2]. Market Position - The company ranks 64th in terms of PE ratio within the medical device industry, which has an average PE of 55.76 and a median PE of 39.14 [1][3]. - As of the first quarter of 2025, five institutions hold shares in the company, with a total of 324,900 shares valued at 2.9 million yuan [1].